1-8 of 8
Gozde Colak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment of Minimal Clinically Important Difference in Patient-Reported Myelofibrosis-Associated Symptoms Using an Anchor-Based Analysis Based on MANIFEST Arm 3 Data

Ruben Mesa, Vikas Gupta, John Mascarenhas, Gabriella Hobbs, Jean-Jacques Kiladjian, Giacomo Coltro, Vincenzo Bagnardi, Chiara Oriecuia, Lennart Kann, Gozde Colak, Claire N Harrison, Debarshi Dey
Journal: Blood
Blood (2023) 142 (Supplement 1): 3195.
https://doi.org/10.1182/blood-2023-179924
Published: 2023
Journal Articles

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Ruben Mesa, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Claire Harrison, Raajit K. Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Gozde Colak, Debarshi Dey, John Mascarenhas
Journal: Blood
Blood (2022) 140 (Supplement 1): 11056–11059.
https://doi.org/10.1182/blood-2022-159389
Published: 2022
Journal Articles

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison
Journal: Blood
Blood (2022) 140 (Supplement 1): 586–589.
https://doi.org/10.1182/blood-2022-158147
Published: 2022
Journal Articles

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas
Journal: Blood
Blood (2022) 140 (Supplement 1): 9659–9662.
https://doi.org/10.1182/blood-2022-157735
Published: 2022
Journal Articles

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Srdan Verstovsek, Mohamed E Salama, John Mascarenhas, Moshe Talpaz, Ruben A. Mesa, Alessandro Vannucchi, Raajit Rampal, Stephen T. Oh, Horatiu Olteanu, April Chiu, Dong Chen, Curtis A. Hanson, Natalia Curto-Garcia, Pietro Taverna, Jike Cui, Oksana Zavidij, Zehua Chen, Gozde Colak, Sergey Efuni, Patricia J Keller, Patrick Trojer, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 2568.
https://doi.org/10.1182/blood-2021-152267
Published: 2021
Journal Articles

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Marina Kremyanskaya, John Mascarenhas, Francesca Palandri, Alessandro Vannucchi, Srdan Verstovsek, Claire N. Harrison, Prithviraj Bose, Gary J. Schiller, Raajit Rampal, Mark W. Drummond, Vikas Gupta, Andrea Patriarca, Nikki Granacher, Joseph Scandura, Witold Prejzner, Lino L. Teichmann, Natalia Curto-Garcia, Ronald Hoffman, Gozde Colak, Zheng Ren, Suresh Bobba, Jike Cui, Sergey Efuni, Moshe Talpaz
Journal: Blood
Blood (2021) 138 (Supplement 1): 141.
https://doi.org/10.1182/blood-2021-150172
Published: 2021
Journal Articles

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Jennifer A Mertz, PhD, Patricia J Keller, PhD, Rosana D Meyer, MD, Oksana Zavidij, PhD, Jike Cui, PhD, Jean-Jacques Kiladjian, MD PhD, Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Moshe Talpaz, MD, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Ruben Mesa, MD, John Mascarenhas, MD, Adrian Senderowicz, MD, Gozde Colak, PhD, James Shao, MS, Katarina Luptakova, MD, Jeffrey S Humphrey, MD, Jing Wang, PhD, Patrick Trojer, PhD, Mohamed E Salama, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-138752
Published: 2020
Journal Articles

MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

John Mascarenhas, MD, Claire Harrison, DM, FRCP, FRCPath, Katarina Luptakova, MD, Jessica Christo, MA, Jing Wang, PhD, Jennifer A Mertz, PhD, Gozde Colak, PhD, James Shao, MS, Suresh Bobba, MD, Patrick Trojer, PhD, Adrian Senderowicz, MD, Jeffrey S Humphrey, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43.
https://doi.org/10.1182/blood-2020-140901
Published: 2020